Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-Omburtamab and Radiotherapy in Desmoplastic Small Round Cell Tumor
NCT04022213Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2019
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 131I-omburtamab in desmoplastic small round cell tumor (DSRCT), primary peritoneal cancer (PPC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2019; status: active, not recruiting.
02
Drugs
131I-omburtamab
03
Conditions
desmoplastic small round cell tumor (DSRCT)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04022213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04022213.